** Ebiogen Launches Urine-Based Cocaine Drug Detection Kit Following Advertising Review Approval **
2026-07-02
본문
Ebiogen Inc. is pleased to announce that its urine-based single-drug cocaine detection kit, BN1C-COC, has successfully passed the required advertising review and is now available on the market. The new product will be supplied and sold together with Ebiogen’s existing urine-based single-drug methamphetamine detection kit, BN1C-MET.
BN1C-COC and BN1C-MET are rapid drug detection kits designed to screen urine samples for cocaine and methamphetamine, respectively. With the addition of BN1C-COC to its product portfolio, Ebiogen is expanding its rapid drug screening lineup to help support broader on-site screening for potential drug-related risks.
As concerns over drug misuse and related safety incidents continue to grow, the need for fast, convenient, and practical preliminary screening tools is becoming increasingly important. Ebiogen expects that these products may help support early risk filtering in various fields, including quarantine, transportation, logistics, industrial workplaces, and military or police-related sectors where a high level of mental fitness and safety management is required.
Ebiogen will continue to develop and supply rapid diagnostic solutions that contribute to public health, workplace safety, and broader social security.
